InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy

FHS
June 7, 2024
4:57 am

InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.

5 financial challenges facing the medtech sector: EY

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. As medical device leaders gather this week

October 11, 2023

Screening Kids for Lipid Disorders; Oncology Drugs for Medicare Recipients

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange,

July 23, 2023

Contract for the sale of the MEDICLIN Herzzentrum Coswig has been signed – Biotech Investments

EQS-News: MediClin AG / Key word(s): Disposal/Miscellaneous MEDICLIN: Contract for the sale of the MEDICLIN Herzzentrum Coswig has been signed 23.02.2024 / 15:04 CET/CEST The

February 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.